ENHA is trading at $2.70 (+5.47%) in pre-market action. - This follows a $50 million strategic equity financing agreement announced on June 15, 2026, with tranches expected to close within 45 days. - Investors are also anticipating potential positive impacts from expected peptide reclassification in July 2026, as highlighted in a May 8, 2026, shareholder letter. - The stock previously rose to $2.65 (+3.52%) during the July 2 after-hours session, up from its regular close of $2.56.